Eupraxia Pharmaceuticals Inc. (EPRX) Financial Ratios
9 years of historical data (2017–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
3.71
+4% vs avg
5yr avg: 3.57
30Y Low3.4·High3.8
ROE
↑
-70.0%
↓+67% vs avg
5yr avg: -209.3%
30Y Low-224%·High-70%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
EPRX Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Eupraxia Pharmaceuticals Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $249M | $302M | $108M | — | — | — | — | — | — | — |
| Enterprise Value | $169M | $221M | $75M | — | — | — | — | — | — | — |
| P/E Ratio → | -7.10 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 3.71 | 3.76 | 3.38 | — | — | — | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
EPRX EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — |
EPRX Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -70.0% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -70.0% | -70.0% | -224.1% | -529.9% | -128.1% | -94.3% | — | — | — | -85.8% |
| ROA | -64.9% | -64.9% | -132.9% | -122.3% | -64.7% | -110.4% | -169.1% | -238.0% | -301.4% | -75.0% |
| ROIC | -79478.8% | -79478.8% | — | — | -488.0% | — | — | — | — | — |
| ROCE | -69.7% | -69.7% | -237.3% | -246.0% | -69.5% | -372.5% | — | — | — | -96.4% |
EPRX Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $80M exceeds total debt of $153953, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | 0.00 | 11.71 | 1.25 | 0.52 | — | — | — | 0.00 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.00 | -1.04 | -9.96 | -1.29 | -0.57 | — | — | — | -0.78 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | -41.65 | -23.72 | -18.32 | -17.02 | -1.13 | -4.05 | -103.00 | -95.02 |
Net cash position: cash ($80M) exceeds total debt ($153953)
EPRX Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Eupraxia Pharmaceuticals Inc.'s current ratio of 15.12x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 1.02x to 15.12x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 15.12 | 15.12 | 11.10 | 1.02 | 6.08 | 13.49 | 0.05 | 0.13 | 0.17 | 7.42 |
| Quick Ratio | 15.12 | 15.12 | 11.10 | 1.02 | 6.08 | 13.49 | 0.05 | 0.13 | 0.17 | 7.42 |
| Cash Ratio | 14.31 | 14.31 | 10.67 | 1.00 | 5.97 | 13.19 | 0.01 | 0.06 | 0.06 | 5.46 |
| Asset Turnover | — | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — |
EPRX Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Eupraxia Pharmaceuticals Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | — | — | — | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | — | — | — | — | — | — | — |
| Shares Outstanding | — | $40M | $34M | $24M | $19M | $14M | $13M | $13M | $13M | $13M |
Peer Comparison
Compare EPRX with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 EPRXYou | $249M | -7.1 | — | — | — | — | -70.0% | -79478.8% | — |
 PACB | $426M | -0.8 | — | — | 31.7% | -348.5% | -213.5% | -45.8% | — |
 IRWD | $688M | 28.1 | 8.9 | 5.4 | 99.4% | 40.1% | — | 54.0% | 5.0 |
 PTGX | $6B | -48.5 | — | 113.9 | 97.3% | -343.6% | -20.2% | -21.8% | — |
 NKTR | $2B | -8.4 | — | — | 100.0% | -236.8% | -217.9% | -57.2% | — |
 PRGO | $2B | -1.1 | 7.4 | 11.1 | 35.1% | 8.1% | -39.3% | 3.7% | 5.8 |
 PCRX | $911M | 144.7 | 9.7 | 6.7 | 79.4% | 4.6% | 1.0% | 2.3% | 3.7 |
 HALO | $8B | 25.0 | 8.2 | 11.7 | 78.1% | 58.4% | 153.6% | 73.4% | — |
 PFE | $146B | 18.9 | 10.4 | 16.1 | 70.3% | 24.7% | 8.9% | 7.5% | 3.3 |
 MRK | $275B | 15.3 | 10.6 | 22.3 | 72.0% | 36.2% | 36.9% | 22.0% | 1.7 |
 JNJ | $533B | 38.2 | 18.5 | 26.9 | 69.1% | 24.9% | 20.1% | 20.7% | 1.2 |
| Healthcare Median | — | 22.2 | 14.4 | 18.6 | 64.0% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 9 years · Updated daily
See EPRX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs EPRX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare EPRX vs PACB
Side-by-side business, growth, and profitability comparison vs Pacific Biosciences of California, Inc..
Start ComparisonEPRX — Frequently Asked Questions
Quick answers to the most common questions about buying EPRX stock.
What is Eupraxia Pharmaceuticals Inc.'s P/E ratio?
Eupraxia Pharmaceuticals Inc.'s current P/E ratio is -7.1x. This places it at the 50th percentile of its historical range.
What is Eupraxia Pharmaceuticals Inc.'s ROE?
Eupraxia Pharmaceuticals Inc.'s return on equity (ROE) is -70.0%. The historical average is -120.4%.
Is EPRX stock overvalued?
Based on historical data, Eupraxia Pharmaceuticals Inc. is trading at a P/E of -7.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.